PeptidePedia The community reference

Contributions of GastroparesisGwen

User contributions·21 logged edits·page 1 of 1

Contributions by GastroparesisGwen, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 10,744 edits includes activity predating the current log.

  1. 10:58, 28 May 2026 (diff | hist) Cold chain 27,220 ±0 add the customs-detention point as a logistics fact, sourced
  2. 11:47, 19 Mar 2026 (diff | hist) Qingdao Saber Technology Pharmaceutical 14,372 ±0 m expand §Reception
  3. 23:16, 14 Mar 2026 (diff | hist) Chain of custody 5,157 ±0 expand §What the record contains
  4. 01:40, 5 Mar 2026 (diff | hist) Customs seizure 4,785 ±0 add category for drug regulation
  5. 07:02, 10 Feb 2026 (diff | hist) SURMOUNT trial programme 5,021 ±0 expand §Reading the figures
  6. 05:06, 27 Jan 2026 (diff | hist) High-performance liquid chromatography 7,231 ±0 m give the limit of quantitation with the signal-to-noise ratio it assumes
  7. 09:23, 10 Dec 2025 (diff | hist) Shenzhen Hybio Pharmaceutical 12,268 +136 correct the other-designations row — those are trading variants, not subsidiaries
  8. 23:15, 26 Nov 2025 (diff | hist) Multi-dose vial 22,676 +68 expand §Repeated entry: coring and closure integrity
  9. 10:56, 10 Nov 2025 (diff | hist) Trial data comparison 7,158 ±0 space between number and unit per PP:MOS
  10. 07:33, 4 Oct 2025 (diff | hist) Fmoc chemistry 4,618 ±0 rm the shipping recommendation — that is advice, not description
  11. 08:59, 2 Sep 2025 (diff | hist) Shanghai ERP Biotechnology 6,014 +647 m attribute the capability claim to the organisation's own material
  12. 15:58, 1 Sep 2025 (diff | hist) Adverse effects of GLP-1 receptor agonists 5,791 ±0 add the rebound point with the follow-up study it comes from
  13. 13:16, 3 Jul 2025 (diff | hist) Trifluoroacetate counterion 3,918 ±0 add category for method validation
  14. 07:25, 30 Jun 2025 (diff | hist) Weight regain after discontinuation 4,624 ±0 consistent en dashes in ranges
  15. 18:44, 30 Mar 2025 (diff | hist) SURMOUNT trial programme 3,559 ±0 give the primary endpoint as pre-specified, not as reported
  16. 21:03, 16 Dec 2024 (diff | hist) Adverse effects of GLP-1 receptor agonists 4,129 ±0 move a stray full stop inside the reference
  17. 00:17, 26 Nov 2024 (diff | hist) SURPASS trial programme 3,661 +34 cite the trial publication rather than the sponsor press release
  18. 09:00, 12 Nov 2024 (diff | hist) Underfilling 1,108 +1,108 N create article — testing stub
  19. 04:55, 3 Nov 2024 (diff | hist) Deamidation 2,020 +656 add the counterion determination method by name
  20. 02:25, 16 Oct 2024 (diff | hist) Dulaglutide 2,958 +1,048 give the isoelectric point with the method it was determined by
  21. 09:00, 1 Jul 2024 (diff | hist) Retatrutide 2,390 +2,390 N create article — compound stub